Skip to main content
Terug
CRSP logo

CRISPR Therapeutics AG

Datakwaliteit: 100%
CRSP
NASDAQ Healthcare Biotechnology
€ 46,88
▲ € 0,64 (1,38%)
Marktkapitalisatie: 4,50B
Dagbereik
€ 46,40 € 47,84
52-Weeksbereik
€ 30,04 € 78,48
Volume
1.441.615
50D / 200D Gem.
€ 53,33 / € 55,91
Vorige Slotkoers
€ 46,24

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -7,7 0,4
P/B 2,3 2,9
ROE % -30,2 3,8
Net Margin % -16569,8 3,9
Rev Growth 5Y % -75,1 10,0
D/E 0,2 0,2

Koersdoel Analisten

Hold
€ 65,00 +38.7%
Low: € 33,00 High: € 82,00
Forward WPA
-€ 4,86
Omzet Sch.
49 M

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 18,33
-€ 4,93 – € 87,66
4,9 B 3
FY2029 € 3,16
-€ 0,85 – € 15,11
1,9 B 3
FY2028 -€ 2,47
-€ 11,73 – € 12,57
530 M 9

Belangrijkste Punten

Revenue declined -75,10% annually over 5 years
Debt/Equity of 0,21 — conservative balance sheet
Negative free cash flow of -345,93M
Revenue growth is decelerating — 1Y growth trails 5Y average by 14,87%

Groei

Revenue Growth (5Y)
-75,10%
Revenue (1Y)-89,97%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-30,18%
ROIC-18,40%
Net Margin-16569,77%
Op. Margin-16191,40%

Veiligheid

Debt / Equity
0,21
Current Ratio13,32
Interest Coverage0,00

Waardering

P/E Ratio
-7,74
P/B Ratio2,34
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -89,97% Revenue Growth (3Y) -90,26%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -75,10% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,51M Net Income (TTM) -581,60M
ROE -30,18% ROA -25,67%
Gross Margin -6537,01% Operating Margin -16191,40%
Net Margin -16569,77% Free Cash Flow (TTM) -345,93M
ROIC -18,40% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,21 Current Ratio 13,32
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -7,74 P/B Ratio 2,34
P/S Ratio 1281,99 PEG Ratio -0,17
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 4,50B Enterprise Value 4,54B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,51M 35,00M 370,00M 436.000,0 913,08M
Net Income -581,60M -366,25M -153,61M -650,18M 377,66M
EPS (Diluted) -6,47 -4,34 -1,94 -8,36 4,70
Gross Profit -229,45M -75,25M 239,75M -109,81M 811,90M
Operating Income -568,32M -466,57M -222,54M -673,16M 373,53M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,27B 2,24B 2,23B 2,24B 2,75B
Total Liabilities 343,43M 309,95M 346,77M 367,58M 352,42M
Shareholders' Equity 1,92B 1,93B 1,88B 1,88B 2,40B
Total Debt 394,91M 223,69M 238,63M 244,02M 225,03M
Cash & Equivalents 355,19M 298,26M 389,48M 211,89M 923,03M
Current Assets 1,99B 1,94B 1,91B 1,85B 2,42B
Current Liabilities 149,12M 87,78M 108,79M 121,11M 119,88M